Search
Phenmetrazine
go.drugbank.com/drugs/DB00830ApprovedIllicitA sympathomimetic drug used primarily as an appetite depressant. Its actions and mechanisms are similar to dextroamphetamine.
Cilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigationalCilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigationalTixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.
Regdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawn[A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130] … Trials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020.
Brexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigational[A182186] Currently approved for the treatment of depression, schizophrenia, and agitation associated with dementia due to Alzheimer’s disease, brexpiprazole has also been investigated in other psychiatric … [L46417] Although it is structurally similar to [aripiprazole], brexpiprazole has different binding affinities for dopamine and serotonin receptors.
Flosequinan
go.drugbank.com/drugs/DB13228ApprovedWithdrawnFlosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials.[A174979,L43942]
Categories: Vasodilators Used in Cardiac DiseasesTrioxsalen
go.drugbank.com/drugs/DB04571ApprovedWithdrawnThe photoactivated form produces interstrand linkages in DNA resulting in cell apoptosis. … It is administered either topically or orally in conjunction with UV-A (the least damaging form of ultraviolet light) for phototherapy treatment of vitiligo and hand eczema.
Viomycin
go.drugbank.com/drugs/DB06827ApprovedThese drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. Viomycin was derived from the actinomycete _Streptomyces puniceus_. … Viomycin is a tuberactinomycin antibiotic that was used to treat Mycobacterium tuberculosis until it was replaced by the less toxic capreomycin.
Betahistine
go.drugbank.com/drugs/DB06698ApprovedInvestigationalIt is currently marketed in Canada by various companies, including Teva Pharmaceuticals. … [A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy.
Synonyms: N-methyl-2-pyridineethanamine, N-methyl-2-(2-pyridinyl)ethanamineProducts: BETAVERT N 8MG, BETAVERT N 16MGFlecainide
go.drugbank.com/drugs/DB01195ApprovedInvestigationalWithdrawn[A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. … Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone].
Synonyms: N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamideCategories: Antiarrhythmics, Class I, Antiarrhythmics, Class Ic